Optigo Bio's Therapy
With the aim of reducing barriers to Macular Degeneration treatments, Optigo Bio is developing a truly novel therapy.
Wet AMD Therapy
Optigo Bio is developing a unique biological therapy to deliver highly persistent and long-lasting anti-vascular endothelial growth factor (anti-VEGF) to the retina, with a goal of enhancing the molecule’s residence period within the eye from the current average of 1 to 3 months, to 12 months. Optigo Bio aims to significantly improve treatment adoption, while reducing the patient drop-out rates.
Similar to Wet AMD, when diabetes affects the eye, Diabetic Retinopathy may occur. As blood sugar levels rise, blood vessels within the retina may rupture and bleed or leak fluid into the eye. This may lead to visible blind spots. As the disease progresses, new abnormal blood vessels begin to grow on the damaged blood vessels. Eventually, these abnormal blood vessels, stimulated by the hormone VEGF, will begin to push up against the macula and may cause the macula to shift and become edematous, leading to blurred vision, deteriorating color perception and the appearance of distinct blind spots in the affected eye’s central vision.
Optigo Bio’s AMD therapy will also be suitable to treat diabetic retinopathy by blocking the VEGF hormone and preventing re-growth during the molecule’s residence period.